NCT05421936View on ClinicalTrials.gov

Osimertinib for NSCLC With Uncommon EGFR Mutations

SuspendedOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

September 27, 2020

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions

Carcinoma, Non-Small-Cell LungGenes, erbB-1

Interventions

DRUG

Osimertinib

Treatment as the first EGFR-TKI

Trial Locations (1)

5265601

Sheba Medical Centre, Ramat Gan

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Sheba Medical Center

OTHER_GOV